Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral vector gene therapy; formulation, development, and manufacturing for parenteral dose forms, including prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services...
Website: catalent.com



Growth: Bad revenue growth rate -10.2%, there is slowdown compared to average historical growth rates 7.6%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +89.3%

Profitability: LTM EBITDA margin is negative, -22.6%. On average the margin is decreasing unsteadily. Gross margin is low, +16.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 77.3% higher than minimum and 60.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.5x by EV / Sales multiple , the company can be 78.7% overvalued

Key Financials (Download financials)

Ticker: CTLT
Share price, USD:  (+0.3%)56.5
year average price 46.71  


year start price 47.75 2023-05-07

min close price 31.86 2023-05-16

max close price 59.82 2024-02-05

current price 56.50 2024-05-05
Common stocks: 179 212 982

Dividend Yield:  0.0%
Last revenue growth (y/y):  -10.2%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  7.6%
Historical growth of EBITDA:  -37.3%
EV / Sales: 2.4x
Margin (EBITDA LTM / Revenue): -22.6%
Fundamental value created in LTM:
Market Cap ($m): 10 126
Net Debt ($m): -183
EV (Enterprise Value): 9 943
Price to Book: 2.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-25Zacks Investment Research

TAK or CTLT: Which Is the Better Value Stock Right Now?

2024-04-08Reuters

Novo Nordisk parent refiles US application on Catalent deal

2024-03-29Seeking Alpha

International Companies Drive Diabesity Innovation

2024-03-12Bloomberg Markets and Financ

Novo Owner's CEO on Obesity Sales Boom, Catalent Deal

2024-03-07Reuters

Novo Nordisk expects Catalent deal to close later this year

2024-02-14Reuters

Wegovy packing supplier Catalent lays off 300 workers

2024-02-09Zacks Investment Research

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

2024-02-09Zacks Investment Research

Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

2024-02-09Reuters

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

2024-02-08MarketBeat

Can financial, healthcare, energy stocks rise as rates stay high?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CTLT CTLT CTLT CTLT CTLT CTLT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-14 2023-12-08 2023-12-08 2023-06-12 2023-02-07 2022-11-01
acceptedDate 2024-02-14 14:23:55 2023-12-08 17:06:39 2023-12-08 17:05:20 2023-06-12 16:08:27 2023-02-07 09:26:06 2022-11-01 09:16:12
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 1 024M 982M 1 068M 1 037M 1 149M 1 022M
costOfRevenue 853M 801M 833M 857M 762M 764M
grossProfit 171M 181M 235M 180M 387M 258M
grossProfitRatio 0.167 0.184 0.220 0.174 0.337 0.252
researchAndDevelopmentExpenses 4M 4M 0 0 0 0
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 180M 215M 219M 190M 226M 196M
otherExpenses -3M -13M 4M 15M 23M 2M
operatingExpenses 187M 216M 335M 205M 249M 198M
costAndExpenses 1 040M 1 017M 1 168M 1 062M 1 011M 962M
interestIncome 0 0 0 0 0 0
interestExpense 66M 58M 54M 51M 47M 32M
depreciationAndAmortization 121M 687M 4M 4M 101M 99M
ebitda 105M -48M -96M -21M 239M 159M
ebitdaratio 0.103 -0.049 -0.090 -0.020 0.208 0.156
operatingIncome -16M -735M -100M -25M 138M 60M
operatingIncomeRatio -0.016 -0.748 -0.094 -0.024 0.120 0.059
totalOtherIncomeExpensesNet -166M -713M 4M -257M -24M -57M
incomeBeforeTax -182M -806M -150M -282M 114M 3M
incomeBeforeTaxRatio -0.178 -0.821 -0.140 -0.272 0.099 0.003
incomeTaxExpense 24M -91M -64M -55M 33M 3M
netIncome -206M -715M -86M -227M 81M 0
netIncomeRatio -0.201 -0.728 -0.081 -0.219 0.070 0
eps -1.130 -3.950 -0.480 -1.250 0.450 0
epsdiluted -1.130 -3.950 -0.480 -1.250 0.440 0
weightedAverageShsOut 182M 181M 181M 181M 180M 180M
weightedAverageShsOutDil 182M 181M 181M 181M 184M 181M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CTLT CTLT CTLT CTLT CTLT CTLT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-14 2023-12-08 2023-12-08 2023-06-12 2023-02-07 2022-11-01
acceptedDate 2024-02-14 14:23:55 2023-12-08 17:06:39 2023-12-08 17:05:20 2023-06-12 16:08:27 2023-02-07 09:26:06 2022-11-01 09:16:12
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 229M 209M 280M 252M 442M 281M
shortTermInvestments 0 0 0 0 28M 64M
cashAndShortTermInvestments 229M 209M 280M 252M 470M 345M
netReceivables 1 366M 826M 977M 1 049M 1 450M 1 441M
inventory 775M 811M 764M 744M 841M 753M
otherCurrentAssets 200M 795M 658M 693M 59M 59M
totalCurrentAssets 2 570M 2 641M 2 679M 2 738M 2 918M 2 698M
propertyPlantEquipmentNet 3 777M 3 729M 3 699M 3 671M 3 579M 3 167M
goodwill 2 351M 2 316M 0 3 023M 3 215M 2 929M
intangibleAssets 911M 3 676M 0 1 012M 1 045M 1 017M
goodwillAndIntangibleAssets 3 262M 3 676M 0 4 035M 4 260M 3 946M
longTermInvestments 76M -3 776M 0 0 0 0
taxAssets 55M 100M 0 42M 55M 45M
otherNonCurrentAssets 248M 3 676M 4 404M 344M 335M 349M
totalNonCurrentAssets 7 418M 7 405M 8 103M 8 092M 8 229M 7 507M
otherAssets 0 0 0 0 0 0
totalAssets 9 988M 10 046M 10 782M 10 830M 11 147M 10 205M
accountPayables 407M 367M 427M 394M 367M 379M
shortTermDebt 55M 624M 536M 588M 644M 119M
taxPayables 28M 44M 0 23M 34M 42M
deferredRevenue 214M 179M 0 203M 175M 135M
otherCurrentLiabilities 360M 373M 544M 302M 340M 310M
totalCurrentLiabilities 1 036M 1 543M 1 507M 1 487M 1 526M 943M
longTermDebt 4 959M 4 322M 4 313M 4 261M 4 221M 4 098M
deferredRevenueNonCurrent 5M -68M 0 0 221M 214M
deferredTaxLiabilitiesNonCurrent 50M 68M 0 119M 221M 214M
otherNonCurrentLiabilities 251M 276M 327M 260M 46M 36M
totalNonCurrentLiabilities 5 265M 4 598M 4 640M 4 640M 4 709M 4 562M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 9M 4 322M 0 11M 12M 13M
totalLiabilities 6 301M 6 141M 6 147M 6 127M 6 235M 5 505M
preferredStock 1 055M 883M 0 0 0 0
commonStock 2M 2M 0 2M 2M 2M
retainedEarnings -703M -497M 0 372M 619M 538M
accumulatedOtherComprehensiveIncomeLoss -354M -388M 0 -368M -395M -514M
othertotalStockholdersEquity 3 687M 3 905M 0 4 697M 4 686M 4 674M
totalStockholdersEquity 3 687M 3 905M 4 635M 4 703M 4 912M 4 700M
totalEquity 3 687M 3 905M 4 635M 4 703M 4 912M 4 700M
totalLiabilitiesAndStockholdersEquity 9 988M 10 046M 10 782M 10 830M 11 147M 10 205M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9 988M 10 046M 10 782M 10 830M 11 147M 10 205M
totalInvestments 76M -3 776M 0 0 28M 64M
totalDebt 5 014M 4 946M 4 849M 4 849M 4 865M 4 217M
netDebt 4 785M 4 737M 4 569M 4 597M 4 423M 3 936M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CTLT CTLT CTLT CTLT CTLT CTLT
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-14 2023-12-08 2023-12-08 2023-06-12 2023-02-07 2022-11-01
acceptedDate 2024-02-14 14:23:55 2023-12-08 17:06:39 2023-12-08 17:05:20 2023-06-12 16:08:27 2023-02-07 09:26:06 2022-11-01 09:16:12
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome -206M -759M 0 -227M 81M -2M
depreciationAndAmortization 121M 112M 0 106M 103M 99M
deferredIncomeTax 17M -44M 0 -82M 17M -4M
stockBasedCompensation 16M 19M 0 6M 10M 19M
changeInWorkingCapital 101M 56M 0 -120M -20M -261M
accountsReceivables 5M 160M 0 -130M 117M 31M
inventory -15M -31M 0 45M -95M -85M
accountsPayables 33M -73M 0 29M -16M -52M
otherWorkingCapital 78M -56M 0 -64M -26M -155M
otherNonCashItems 63M 546M 0 253M 23M 57M
netCashProvidedByOperatingActivities 112M -70M 203M -64M 214M -92M
investmentsInPropertyPlantAndEquipment -94M -84M -128M -138M -168M -149M
acquisitionsNet 0 1 000 000 0 0 -474M 0
purchasesOfInvestments -1 000 000 -1 000 000 0 -1 000 000 0 0
salesMaturitiesOfInvestments 0 -1 000 000 0 28M 34M 27M
otherInvestingActivites -1 000 000 1 000 000 0 1 000 000 0 6M
netCashUsedForInvestingActivites -95M -84M -128M -110M -608M -116M
debtRepayment -2M -35M -54M -144M -25M -7M
commonStockIssued 0 1 000 000 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -12M 132M 3M 119M 548M 81M
netCashUsedProvidedByFinancingActivities -14M 98M -51M -25M 523M 74M
effectOfForexChangesOnCash 17M -15M 4M 9M 32M -34M
netChangeInCash 20M -71M 28M -190M 161M -168M
cashAtEndOfPeriod 229M 209M 280M 252M 442M 281M
cashAtBeginningOfPeriod 209M 280M 252M 442M 281M 449M
operatingCashFlow 112M -70M 203M -64M 214M -92M
capitalExpenditure -94M -84M -128M -138M -168M -149M
freeCashFlow 18M -154M 75M -202M 46M -241M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-15 ET (fiscal 2024 q1)
2023 q2
2023-08-29 ET (fiscal 2023 q4)
2023 q1
2023-05-19 ET (fiscal 2023 q3)
2022 q4
2023-02-07 ET (fiscal 2023 q2)
2022 q3
2022-11-01 ET (fiscal 2023 q1)
2022 q2
2022-08-29 ET (fiscal 2022 q4)
2022 q1
2022-05-03 ET (fiscal 2022 q3)
2021 q4
2022-02-02 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2024-03-07 13:00 ET
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
2024-02-09 12:59 ET
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
2024-02-07 14:13 ET
CTLT Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Catalent, Inc. for Potential Securities Law Violations
2024-02-05 15:04 ET
CTLT Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Catalent to Novo Holdings
2024-02-05 11:00 ET
Novo Holdings to Acquire Catalent
2024-01-26 18:35 ET
Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast
2024-01-25 17:00 ET
Catalent Commits to Reducing Greenhouse Gas Emissions by 2030
2024-01-04 13:44 ET
Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 21:15 ET
Catalent Announces Closing of Incremental Term Loans
2023-12-15 13:40 ET
Catalent Regains Compliance with NYSE Continued Listing Standards
2023-12-15 12:30 ET
Awakn Life Sciences Provides Corporate Update
2023-11-15 11:59 ET
Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance
2023-10-31 12:03 ET
Catalent, Inc. Announces First Quarter Fiscal Year 2024 Earnings Conference Webcast
2023-10-04 12:30 ET
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study
2023-09-18 21:00 ET
Catalent Appoints David McErlane as Biologics Segment Leader
2023-09-15 11:00 ET
Catalent Receives NYSE Notice Regarding Late Form 10-K Filing
2023-09-14 11:30 ET
Awakn Life Sciences Provides Corporate Update
2023-09-07 13:11 ET
Catalent, Inc. to Present at September Investor Conferences
2023-08-29 11:15 ET
Catalent Announces Governance Enhancements and New Initiatives to Drive Value
2023-08-29 11:00 ET
Catalent, Inc. Reports Preliminary Fourth Quarter and Fiscal 2023 Results
2023-08-22 13:14 ET
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2023 Earnings Conference Webcast
2023-08-01 13:00 ET
Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer
2023-06-20 20:15 ET
Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer
2023-06-13 20:53 ET
Catalent Regains Compliance with NYSE Continued Listing Standards
2023-06-12 10:59 ET
Catalent, Inc. Reports Third Quarter Fiscal 2023 Results
2023-06-09 20:19 ET
Catalent, Inc. Announces Third Quarter Fiscal Year 2023 Earnings Conference Webcast
2023-05-19 11:00 ET
Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing
2023-05-13 00:15 ET
Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call
2023-05-08 11:45 ET
Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance
2023-05-05 20:30 ET
Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation
2023-04-14 11:30 ET
Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer
2023-04-12 13:30 ET
CATALENT, INC. INVESTOR ADVISORY: April 25, 2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-04-06 13:45 ET
CATALENT, INC. SHAREHOLDERS ALERT: April 25, 2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-04-03 13:45 ET
CATALENT, INC. SHAREHOLDERS: 4/25/2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-29 13:30 ET
CATALENT, INC. INVESTORS: 4/25/2023 Plaintiff Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-03-28 13:20 ET
CATALENT, INC. INVESTOR ADVISORY: 4/25/2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-23 13:50 ET
CATALENT, INC. INVESTOR ADVISORY: 4/25/2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-20 13:50 ET
CATALENT, INC. INVESTOR WARNING: 4/25/2023 Plaintiff Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-15 13:50 ET
CATALENT, INC. INVESTOR WARNING: 4/25/2023 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
2023-03-14 13:15 ET
Catalent, Inc. Investor Warning: 4/25/2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-13 17:19 ET
CATALENT, INC. INVESTORS: April 25, 2023 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
2023-03-09 21:31 ET
Catalent, Inc. to Present at March Investor Conferences
2023-03-06 13:30 ET
Catalent Appoints Sridhar Krishnan to Lead New Global Operational Excellence Strategy, “The Catalent Way”
2023-03-03 18:30 ET
Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use
2023-02-28 13:30 ET
Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments
2023-02-13 13:00 ET
Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary
2023-02-09 12:30 ET
Awakn Life Sciences Initiates Feasibility Study for MDMA Using Catalent's Zydis Orally Disintegrating Tablet (ODT) Technology
2023-02-07 11:59 ET
Catalent, Inc. Reports Second Quarter Fiscal 2023 Results
2023-01-20 13:38 ET
Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast
2023-01-17 13:00 ET
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
2023-01-09 12:30 ET
Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement
2023-01-03 22:15 ET
Catalent, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-19 13:00 ET
Catalent Announces Changes to its Board of Directors
2022-12-15 12:30 ET
Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth
2022-11-08 21:02 ET
Catalent, Inc. to Present at the Stephens Annual Investment Conference
2022-11-01 10:59 ET
Catalent, Inc. Reports First Quarter Fiscal 2023 Results
2022-10-17 21:12 ET
Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast
2022-09-15 11:30 ET
Awakn Life Sciences Reports Strong Q2 2022 Results
2022-09-12 11:30 ET
Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
2022-09-08 20:29 ET
Catalent, Inc. to Present at September Investor Conferences
2022-08-29 10:59 ET
Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results
2022-08-09 22:30 ET
Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity
2022-08-05 12:50 ET
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast
2022-07-21 20:30 ET
Marvel Announces Identification of a Novel Formulation of Its MB-204 Asset
2022-07-05 12:00 ET
Catalent Announces New Operating Structure
2022-05-27 12:26 ET
Catalent, Inc. to Present at June Investor Conferences
2022-05-03 10:59 ET
Catalent, Inc. Reports Third Quarter Fiscal 2022 Results
2022-04-15 13:00 ET
Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast
2022-04-06 13:00 ET
Marvel Biosciences Initiates Formulation Development with Catalent
2022-03-18 12:30 ET
Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
2022-03-10 13:30 ET
Catalent Publishes Third Annual Corporate Responsibility Report
2022-02-01 12:00 ET
Catalent, Inc. Reports Second Quarter Fiscal 2022 Results
2022-01-21 13:15 ET
Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
2022-01-19 12:30 ET
ElevateBio Announces Andrew Sandford Joins as President of ElevateBio BaseCamp
2022-01-05 13:00 ET
Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022
2022-01-03 21:15 ET
Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-07 12:00 ET
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
2021-11-23 22:15 ET
Catalent, Inc. to Present at the Stephens Annual Investment Conference
2021-11-02 11:00 ET
Catalent, Inc. Reports First Quarter Fiscal 2022 Results
2021-10-20 21:15 ET
Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast
2021-09-23 22:49 ET
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030
2021-09-23 11:49 ET
Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030
2021-09-07 11:45 ET
Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-30 11:00 ET
Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer
2021-08-30 11:00 ET
Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent
2021-08-30 11:00 ET
Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results
2021-08-30 11:00 ET
Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent
2021-08-06 13:00 ET
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast
2021-08-03 13:00 ET
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
2021-06-28 12:03 ET
Cybin Inc. Releases Annual Financials and Provides Business Highlights
2021-06-04 13:00 ET
Catalent, Inc. to Present at the Biopharma CEO Investor Forum
2021-05-28 12:48 ET
Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference
2021-05-21 12:45 ET
Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference
2021-05-13 12:59 ET
Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry
2021-05-11 11:00 ET
Catalent Announces Chief Financial Officer Succession
2021-05-07 13:00 ET
Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference
2021-05-04 10:59 ET
Catalent, Inc. Reports Third Quarter Fiscal 2021 Results
2021-04-19 12:30 ET
Catalent, Inc. Announces Third Quarter Fiscal Year 2021 Earnings Conference Webcast
2021-03-22 11:15 ET
Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
2021-02-19 21:15 ET
Catalent, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-10 21:49 ET
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029
2021-02-10 12:44 ET
Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029
2021-02-02 12:15 ET
Catalent, Inc. Reports Second Quarter Fiscal 2021 Results
2021-01-20 13:45 ET
Catalent, Inc. Announces Second Quarter Fiscal Year 2021 Earnings Conference Webcast
2021-01-06 13:55 ET
Catalent, Inc. to Present at the 39th Annual J.P. Morgan Healthcare Conference
2020-11-11 14:16 ET
Catalent, Inc. to Present at November 2020 Virtual Investor Conferences
2020-11-03 12:15 ET
Catalent, Inc. Reports First Quarter Fiscal 2021 Results
2020-10-22 13:00 ET
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
2020-10-16 13:00 ET
Catalent, Inc. Announces First Quarter Fiscal Year 2021 Earnings Conference Webcast
2020-09-03 12:00 ET
Catalent, Inc. to Present at September 2020 Virtual Investor Conferences
2020-08-31 11:15 ET
Catalent, Inc. Reports Fourth Quarter Fiscal 2020 Results
2020-08-24 12:00 ET
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
2020-07-30 12:13 ET
Catalent, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2020 Net Revenue, Earnings Before Income Taxes, and Adjusted EBITDA Significantly Ahead of Its Previous Guidance
2020-06-25 11:30 ET
Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
2020-06-15 11:30 ET
Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate
2020-06-10 20:07 ET
Catalent, Inc. Announces Public Offering of Common Stock
2020-05-28 20:16 ET
Catalent, Inc. to Present at June 2020 Virtual Investor Conferences
2020-05-08 20:05 ET
Catalent, Inc. to Present at May 2020 Virtual Investor Conferences
2020-05-05 11:28 ET
Catalent, Inc. Reports Third Quarter Fiscal 2020 Results
2020-05-04 12:46 ET
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
2020-04-30 20:30 ET
Catalent Announces Next Generation of Cell & Gene Therapy Leadership
2020-04-29 12:00 ET
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
2020-04-15 20:05 ET
Catalent, Inc. Announces Third Quarter Fiscal Year 2020 Earnings Conference Webcast
2020-04-13 23:44 ET
Catalent Publishes Fiscal 2019 Corporate Responsibility Report
2020-03-09 22:45 ET
Catalent, Inc. to Present at the Barclays Global Healthcare Conference
2020-02-20 18:04 ET
Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2028
2020-02-19 07:55 ET
Catalent Announces Launch of Private Offering of €450 Million of Senior Unsecured Notes Due 2028
2020-02-18 21:05 ET
Catalent, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-10 21:15 ET
Catalent Completes Acquisition of MaSTherCell
2020-02-03 21:12 ET
Catalent, Inc. Announces Public Offering of Common Stock
2020-02-03 12:30 ET
Catalent, Inc. Reports Second Quarter Fiscal 2020 Results
2020-02-03 12:29 ET
 Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform
2020-01-16 21:15 ET
Catalent Further Strengthens Biologics Business with Key Senior Appointments
2020-01-15 21:15 ET
Catalent, Inc. Announces Second Quarter Fiscal Year 2020 Earnings Conference Webcast
2020-01-07 21:15 ET
Catalent, Inc. to Present at the 38th Annual J.P. Morgan Health Care Conference

SEC forms

Show financial reports only

SEC form 10
2024-02-14 00:00 ET
Catalent reported for 2023 q4
SEC form 8
2024-02-09 00:00 ET
Catalent published news for 2023 q4
SEC form 8
2024-02-09 00:00 ET
Catalent reported for 2023 q4
SEC form 10
2023-12-08 00:00 ET
Catalent reported for 2023 q2
SEC form 10
2023-12-08 00:00 ET
Catalent reported for 2023 q3
SEC form 8
2023-11-15 07:05 ET
Catalent reported for 2023 q3
SEC form 8
2023-08-29 00:00 ET
Catalent reported for 2023 q2
SEC form 6
2023-07-07 16:26 ET
Catalent published news for 2023 q2
SEC form 10
2023-06-12 16:08 ET
Catalent reported for 2023 q1
SEC form 6
2023-06-12 15:58 ET
Catalent published news for 2023 q1
SEC form 6
2023-06-12 07:12 ET
Catalent reported for 2023 q1
SEC form 8
2023-06-12 00:00 ET
Catalent published news for 2023 q1
SEC form 10
2023-06-12 00:00 ET
Catalent published news for 2023 q1
SEC form 6
2023-05-19 08:00 ET
Catalent published news for 2023 q1
SEC form 8
2023-05-19 00:00 ET
Catalent published news for 2023 q1
SEC form 6
2023-05-12 21:14 ET
Catalent published news for 2023 q1
SEC form 6
2023-05-11 17:03 ET
Catalent published news for 2023 q1
SEC form 6
2023-05-08 08:02 ET
Catalent published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Catalent published news for 2023 q1
SEC form 6
2023-04-14 07:53 ET
Catalent published news for 2023 q1
SEC form 8
2023-04-14 00:00 ET
Catalent published news for 2023 q1
SEC form 6
2023-02-21 10:10 ET
Catalent published news for 2022 q4
SEC form 10
2023-02-07 09:26 ET
Catalent published news for 2022 q4
SEC form 6
2023-02-07 07:05 ET
Catalent published news for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Catalent reported for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Catalent reported for 2022 q4
SEC form 6
2023-02-06 19:20 ET
Catalent published news for 2022 q4
SEC form 6
2022-12-19 08:14 ET
Catalent published news for 2022 q3
SEC form 6
2022-11-22 16:37 ET
Catalent published news for 2022 q3
SEC form 10
2022-11-01 09:16 ET
Catalent published news for 2022 q3
SEC form 6
2022-11-01 07:04 ET
Catalent published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Catalent reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Catalent reported for 2022 q3
SEC form 6
2022-09-23 16:05 ET
Catalent published news for 2022 q2
SEC form 6
2022-09-19 16:41 ET
Catalent published news for 2022 q2
SEC form 6
2022-09-16 08:01 ET
Catalent published news for 2022 q2
SEC form 10
2022-08-29 09:21 ET
Catalent published news for 2022 q2
SEC form 6
2022-08-29 07:04 ET
Catalent published news for 2022 q2
SEC form 8
2022-08-29 00:00 ET
Catalent reported for 2022 q2
SEC form 10
2022-08-29 00:00 ET
Catalent reported for 2022 q2
SEC form 6
2022-07-05 08:37 ET
Catalent published news for 2022 q2
SEC form 10
2022-05-03 09:08 ET
Catalent published news for 2022 q1
SEC form 6
2022-05-03 07:48 ET
Catalent published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Catalent reported for 2022 q1
SEC form 10
2022-05-03 00:00 ET
Catalent reported for 2022 q1
SEC form 10
2022-02-01 09:17 ET
Catalent published news for 2021 q4
SEC form 6
2022-02-01 07:05 ET
Catalent published news for 2021 q4
SEC form 10
2022-02-01 00:00 ET
Catalent published news for 2021 q4
SEC form 8
2022-02-01 00:00 ET
Catalent published news for 2021 q4
SEC form 6
2022-01-05 08:15 ET
Catalent published news for 2021 q4
SEC form 10
2021-11-02 09:11 ET
Catalent published news for 2021 q3
SEC form 6
2021-11-02 07:10 ET
Catalent published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Catalent published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Catalent published news for 2021 q3
SEC form 6
2021-09-29 16:32 ET
Catalent published news for 2021 q2
SEC form 6
2021-09-23 19:06 ET
Catalent published news for 2021 q2
SEC form 6
2021-09-23 07:54 ET
Catalent published news for 2021 q2
SEC form 6
2021-09-17 07:31 ET
Catalent published news for 2021 q2
SEC form 6
2021-09-03 16:41 ET
Catalent published news for 2021 q2
SEC form 10
2021-08-30 09:26 ET
Catalent published news for 2021 q2
SEC form 6
2021-08-30 07:15 ET
Catalent published news for 2021 q2
SEC form 10
2021-08-30 00:00 ET
Catalent published news for 2021 q2
SEC form 8
2021-08-30 00:00 ET
Catalent published news for 2021 q2
SEC form 6
2021-05-20 16:33 ET
Catalent published news for 2021 q1
SEC form 6
2021-05-11 07:30 ET
Catalent published news for 2021 q1
SEC form 10
2021-05-04 09:03 ET
Catalent published news for 2021 q1
SEC form 6
2021-05-04 07:07 ET
Catalent published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Catalent published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Catalent published news for 2021 q1
SEC form 6
2021-02-22 16:27 ET
Catalent published news for 2020 q4
SEC form 6
2021-02-10 17:29 ET
Catalent published news for 2020 q4
SEC form 6
2021-02-10 07:50 ET
Catalent published news for 2020 q4
SEC form 10
2021-02-02 08:15 ET
Catalent published news for 2020 q4
SEC form 6
2021-02-02 07:21 ET
Catalent published news for 2020 q4
SEC form 10
2020-11-03 08:10 ET
Catalent published news for 2020 q3
SEC form 6
2020-11-03 07:13 ET
Catalent published news for 2020 q3
SEC form 6
2020-09-18 07:30 ET
Catalent published news for 2020 q2